Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer

Yonsei Medical Journal

Volumn 44, Issue 4, 2003, Pages 665-675

  Kim, Dong Joo ^a   Kim, Tae Il ^a   Suh, Jung Hoo ^a   Cho, Yong Suk ^a   Shin, Sung Kwan ^a   Kang, Jin Kyung ^a   Kim, Nam Kyu ^a   Kim, Won Ho ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Colon cancer; Folinic acid; Tegafur uracil

Indexed keywords

FLUOROURACIL; FOLINIC ACID; UFT;

ANEMIA; ARTICLE; BLEEDING DISORDER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON CANCER; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DETERIORATION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; INFECTION; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MODULATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PATIENT COMPLIANCE; POSTOPERATIVE CARE; QUALITY OF LIFE; SCORING SYSTEM; SEPSIS; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 0041379123     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2003.44.4.665     Document Type: Article

References (48)

1. National Institutes of Health Consensus Development Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50.
2. Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson RW, et al. (Advanced Colorectal Cancer Meta-Analysis Project). Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
3. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
4. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
5. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, et al. The benefit of leucovorin modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 1993;11:1879-87.
6. Wolmark N, Rockette H, Mamounas EP, Jones J, Petrelli N, Atkins J, et al. The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes B and C carcinoma of the colon: first report of NSABP C-04. Proc ASCO (Am Soc Clin Oncol) 1996; 15:205 (abstr 460).
7. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
8. O'Connell M, Mailliard J, Macdonald J, Haller D, Mayer R, Wieand H. An intergroup trial of intensive course 5-FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer. Proc ASCO 1993;12:190 (abstr 552).
9. Mamounas EP, Wieand HS, Jones J, Wickerham DL, Wolmark N. Future directions in the adjuvant treatment of colon cancer. Oncology 1997;11(9 Suppl 10): 44-7.
10. Chabner BA. Pyrimidine antagonists. In: Chabner BA, editor. Pharmacologic Principles of Cancer Treatment. Philadelphia: Saunders; 1982. p.183-212.
11. Spiegelman S, Sawyer R, Nayak R, Ritzi E, Stolfi R, Martin D. Improving the antitumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc Natl Acad Sci USA 1980;77:4966-70.
12. Lockshin A, Danenberg PV. Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol 1981;30:247-57.
13. Yin M-B, Zakrzewski SF, Hakala MT. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 1983;23:190-7.
14. Evans RM, Laskin JD, Hakala MT. Effects of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 1981;41:3288-95.
15. Taguchi T. Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU. Oncology 1995;54 Suppl 1:12-8.
16. Taguchi T, Hanano Y, Jikyua K, Fujii S. Effect of uracil on the antitumor activity of ftorafur. Jpn J Cancer Chemother 1978;5:1161-5.
17. Rustum YM. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology 1997;54 Suppl 1:7-11.
18. Fujii S, Kitano S, Ikenaka K, Shirasaka T. Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Chemother (Gan to Kagaku Ryoho) 1979;6:377-84.
19. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988;22:333-8.
20. Tashiro H, Nomura Y, Ohsaki A. A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer. Jpn J Clin Oncol 1994;24:212-7.
21. Kurihara M, Izumi T, Yoshida S, Ohkubo T, Suga S, Kiyohashi A, et al. A cooperative randomized study of tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 1991;82:613-20.
22. Ikeda E, Kodaira S, Teramoto T, Okuda M, Takahashi T, Kato T, et al. Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer: phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration-Study Group of UFTM Therapy for Advanced Colorectal Cancer. Jpn J Cancer Chemother 1996;23:1291-8.
23. Wada H, Hitomi S, Teramatsu T, West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 1996;14:1048-54.
24. Wada H, Tanaka F, Hitomi S. Postoperative adjuvant chemotherapy for non-small-cell lung cancer. Oncology (Huntingt) 1997;11(9 Suppl 10):98-102.
25. Kim YH, Cheong SK, Lee JD, Park JS, Shin SW, Kim JS. Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma. Am J Clin Oncol 1996;19: 212-6.
26. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296-300.
27. Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. Cancer 1995;75:782-5.
28. Gonzalez Baron M, Feliu J, Garcia Giron C, Espinosa J, Martinez B, Blanco E, et al. UFT® modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. Oncology 1997;54 Suppl 1:24-9.
29. Ganz PA. Long-range effect of clinical trial interventions on quality of life. Cancer 1994;74:2620-4.
30. Ganz PA, Lee JJ, Siau J. Quality of life assessment: an independent prognostic variable for survival in lung cancer. Cancer 1991;67:3131-5.
31. Aaronson NK. Quality-of-life : what is it? how should it be measured? Oncology (Huntingt) 1988;2:69-76.
32. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994; 12:608-16.
33. World Health Organization. WHO handbook for reporting results of cancer treatment (Offset publication 48). World Health Organization, Geneva, 1979.
34. Kurihara M, Nakamura H, Matsukawa M, Takemoto T, Hirashima M, Wakasugi S, et al. Assessment of QOL in cancer drug therapy using 22-item questionnaire. Jpn J Cancer Chemother 1993;21:379-87.
35. Hiller SA, Zhuk RA, Lidak MY. Analogs of pyrimidine nucleosides. Dokl Akad Nauk SSSR 1967;176:332-5.
36. Blokhina NG, Vozny EK, Garin AM. Results of treatment of malignant tumors with ftorafur. Cancer 1972; 30:390-2.
37. Valdivieso M, Bodey GP, Gottlieb JA, Freireich EJ. Clinical evaluation of ftorafur (pyrimidine-deoxyribose N1-2′-furanidyl-5-fluorouracil). Cancer Res 1976;36: 1821-4.
38. Anttila MI, Sotaniemi EA, Kairaluoma MI, Mokka RE, Sundquist HT. Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Phamacol 1983;10:150-3.
39. Fujji S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978;69:763-72.
40. Tsujimoto T, Sakai S, Murata M. Concentration of 5-FU in the tissue and serum of patients with head and neck malignant tumors by preoperative administration of UFT. Jpn J Cancer Chemother 1983;10:78-83.
41. Suemasu K, Azuma Y, Nomoto M. Concentration of 5-FU level in the tissue and blood of patients with breast cancer by preoperative administration of UFT. Jpn J Cancer Chemother 1982;9:667-71.
42. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
43. Petrelli N, Douglass Jr HO, Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7:1419-26.
44. Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6:469-75.
45. Keyomarsi K, Moran RG. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 1986;46:5229-35.
46. McGuire BW, Sia LL, Haynes JD, Kisicki JC, Gutierrez ML, Stokstad EL. Absorption kinetics of orally administered leucovorin calcium. NCI Monogr 1987;5:47-56.
47. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal carcinoma. J Clin Oncol 1994;12:14-20.
48. Hansen RM, Ryan L, Anderson T, Krzywda B, Quebbeman E, Benson III A, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996;88:668-74.